Viropro Inc. and Oncobiologics, Inc. announced the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries. Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia.

In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization. The six biosimilars are generic versions of Humira(R), Rituxan(R), Avastin(R), Herceptin(R), Erbitux(R) and one other non-disclosed biotherapeutic.